Car-T comes full circle
Bristol renews its focus on chronic lymphocytic leukaemia, but rivals haven’t fared so well here.
A new order in BTK inhibition
Imbruvica faces challenges on multiple fronts.
Lilly makes steady progress in non-covalent BTK inhibition
Jaypirca secures a CLL label, though plans to dominate will be tempered by this market’s fast-changing nature.
